Header Logo

Connection

DAVID GRAHAM to Antacids

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Antacids.
DAVID GRAHAM
Connection Strength
4.057
Antacids
  1. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.716
  2. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 07; 155(1):67-75.
    View in: PubMed
    Score: 0.589
  3. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May; 65(5):870-8.
    View in: PubMed
    Score: 0.509
  4. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.488
  5. Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. Aliment Pharmacol Ther. 2015 Jun; 41(11):1220-1.
    View in: PubMed
    Score: 0.486
  6. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct; 25(10):1134-40.
    View in: PubMed
    Score: 0.433
  7. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.237
  8. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr; 148(4):719-31.e3.
    View in: PubMed
    Score: 0.119
  9. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. World J Gastroenterol. 2014 Sep 07; 20(33):11467-85.
    View in: PubMed
    Score: 0.115
  10. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011 Jun 14; 183(9):E506-8.
    View in: PubMed
    Score: 0.090
  11. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.057
  12. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983 Jun; 28(6):559-63.
    View in: PubMed
    Score: 0.053
  13. Why do apparently healthy people use antacid tablets? Am J Gastroenterol. 1983 May; 78(5):257-60.
    View in: PubMed
    Score: 0.053
  14. Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pancreatic insufficiency: an animal model. Gastroenterology. 1982 Sep; 83(3):638-44.
    View in: PubMed
    Score: 0.050
  15. Treatment of steatorrhea in chronic pancreatitis. Hosp Pract (Off Ed). 1986 Jan 15; 21(1):125-9.
    View in: PubMed
    Score: 0.016
  16. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003 Aug; 8(4):307-9.
    View in: PubMed
    Score: 0.013
  17. Pancreatic enzyme replacement: the effect of antacids or cimetidine. Dig Dis Sci. 1982 Jun; 27(6):485-90.
    View in: PubMed
    Score: 0.012
  18. Double-blind multicenter comparison of 1,200 mg. and 1,000 mg. cimetidine in hospitalized and ambulatory duodenal ulcer patients. Am J Gastroenterol. 1981 Dec; 76(6):500-5.
    View in: PubMed
    Score: 0.012
  19. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.